Clinical Trials Logo

Hepatic Failure clinical trials

View clinical trials related to Hepatic Failure.

Filter by:

NCT ID: NCT06179368 Recruiting - Hepatic Impairment Clinical Trials

Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome

Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

Liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (T4) to triiodothyronine (T3) by Type 1 deiodinase.

NCT ID: NCT05604469 Recruiting - Renal Failure Clinical Trials

The Role of Skin Microbiota in Hepatic or Renal Pruritus

Start date: October 1, 2022
Phase:
Study type: Observational [Patient Registry]

- Various neurotransmitters may share in the pathogenesis of hepatic and renal itching. - Skin microbiota may share in the pathogenesis of pruritus.

NCT ID: NCT04587622 Completed - Hepatic Failure Clinical Trials

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

Start date: October 30, 2020
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics, safety, and tolerability of icenticaftor in participants with varying degrees of hepatic impairment.

NCT ID: NCT03576859 Completed - Hepatic Failure Clinical Trials

Pyrophosphate Homeostasis and Hepatic Expression of ABCC6.Pyro-TH

Pyro-TH
Start date: November 6, 2018
Phase: N/A
Study type: Interventional

In animals, normal hepatic expression of ABCC6 (ATP-binding transporter cassette, subfamily C, member 6) determines plasma pyrophosphate (PPi) concentration. PPi prevents the formation of hydroxyapatite crystals on tissues by precipitation of calcium and inorganic phosphate (Pi). It is an endogenous compound whose deficiency causes diffuse vascular calcifications in certain rare monogenic diseases, including the elastic pseudoxanthoma caused by the mutation of ABCC6. PPi is produced by enzymatic transformation of extracellular ATP and, in animals, the liver is the main supplier of ATP and PPi (more than 90%). In humans, liver transplantation offers the possibility of correlating the plasma concentration of PPi ([PPi]pl) with hepatic expression of ABCC6. Liver transplantation is performed in the treatment of chronic liver failure (Child B or C) or, in the absence of liver failure, in the treatment of hepatocellular carcinoma. By measuring[PPi]pl before transplantation and after liver function restoration and by measuring ABCC6 in the diseased liver and healthy liver, it is possible to determine whether liver failure is associated with decreased[PPi]pl and decreased liver expression of ABCC6, which is the objective of our pilot study. Its interest is to establish a physiopathological link between the frequent vascular calcifications in obese patients with hepatic steatosis and the production of PPi. prupose: Look for a deficit in[PPi]pl in patients before the transplant compared to the phase of restoration of liver function

NCT ID: NCT03560414 Not yet recruiting - Hepatic Failure Clinical Trials

The Plasma Diafiltration Therapy of Hepatic Failure

Start date: June 2018
Phase: N/A
Study type: Interventional

At present, there is no comparative study between the simple plasma exchange and plasma diafiltration (PDF), and no further exploration of optimal plasma dose in PDF treatment. Therefore, this prospective randomized cohort study aims to compare the safety and effectiveness of the tree groups(simple plasma exchange group, conventional PDF treatment group, less plasma PDF treatment group)by collecting SOFA score, 3-month survival rate, MELD score, and the times of artificial liver treatment , blood cell variables, cytokines(e.g. TNFα ), pre- and post-treatment plasma ammonia levels. Thus, it is to provide a safer and more effective artificial liver treatment with less plasma dose.

NCT ID: NCT03515980 Completed - Clinical trials for Congestive Heart Failure

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

Start date: May 25, 2018
Phase: Phase 1
Study type: Interventional

This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.

NCT ID: NCT02552901 Withdrawn - Liver Failure Clinical Trials

Cardiox Liver Function Test Pivotal Trial

LFT-0002
Start date: November 2015
Phase: Phase 3
Study type: Interventional

Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum ICG PDR.

NCT ID: NCT02516319 Terminated - Hepatic Failure Clinical Trials

Liver Function Assessment - Feasibility and Dosing Study

Start date: September 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to 1) determine the feasibility of using Cardiox Liver Function Assessment System (LFA) to measure indocyanine green (ICG) clearance; 2) determine an adequate dose based on LFA technology and 3) determine an adequate time period for LFA determination.

NCT ID: NCT01846455 Completed - Hepatic Impairment Clinical Trials

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Start date: August 2012
Phase: Phase 4
Study type: Interventional

Pharmacokinetics of Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment and in HCV-Seropositive Subjects, and in Healthy Volunteers.

NCT ID: NCT00831532 Completed - Hepatic Failure Clinical Trials

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

Start date: February 2009
Phase: Phase 1
Study type: Interventional

1. To compare the pharmacokinetics of Dimebon in subjects with mild and moderate hepatic impairment to subjects with normal hepatic function. 2. To assess the safety and tolerability of Dimebon in subjects with hepatic impairment and subjects with normal hepatic function. 3. To explore the pharmacokinetics of Dimebon in subjects with severely-impaired hepatic function.